An interventional study of Prasugrel and Ticagrelor in ST Elevation Myocardial Infarction, sponsored by AORTICA Group. Completed at 1 site in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-06-10.
Sponsored by AORTICA Group · Not applicable, Interventional, and Treatment
Among 13 studies testing prasugrel in ST Elevation Myocardial Infarction — none open to participants now, none under way, none of them phase 3. prasugrel · ST Elevation Myocardial Infarction.
Among the 13 studies testing prasugrel in ST Elevation Myocardial Infarction, this one is the 9th largest by enrollment, is one of 2 that started in 2015, is the only one with no phase, and was the 12th registered.
850 studies on the registry are indexed under ST Elevation Myocardial Infarction; 197 are open to participants now.
Browse ST Elevation Myocardial Infarction studies →None of the 13 studies testing prasugrel in ST Elevation Myocardial Infarction is open now.
prasugrel: first FDA approval 2009 (EFFIENT), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 122 ST Elevation Myocardial Infarction studies recruiting now, 76 (62%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 6 · Phase 4 6
First in 2010; this study’s year is marked. 2 started in 2015.
This study's enrollment of 61 is below the median of 194 across 527 interventional studies indexed under ST Elevation Myocardial Infarction.
Median enrollment 82 across the 13 interventional studies. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 13 have an industry lead sponsor. The 10 most frequent:
AORTICA Group is the lead sponsor of 5 studies on the registry; none are open to participants now.
AORTICA Group has 1 study filed under ST Elevation Myocardial Infarction — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing prasugrel in ST Elevation Myocardial Infarction, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The investigators propose to perform a randomized clinical trial comparing prasugrel vs. ticagrelor in 60 patients with ST elevation acute myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention. The principal objective of the study would be analyzing the difference in myocardial infarction size measured by cardiac magnetic resonance at 6 months
Dual antiplatelet therapy consisting of aspirin and one of the P2Y12 receptor inhibitors is the mainstay of treatment for patients with ST elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Prasugrel or ticagrelor have actually shown to be superior to clopidogrel improving the prognosis of these patients. However, the industrial interest has avoided any direct comparison between these two antiplatelets. Comparison is of great interest considering that only ticagrelor has shown to significantly reduce mortality. As ticagrelor may exert off-target effects through adenosine-related mechanisms, the investigators aimed to investigate whether ticagrelor reduces myocardial injury to a greater extent than prasugrel in patients with revascularized STEMI.
Patients with acute STEMI undergoing primary percutaneous coronary revascularization within 6 hours of chest pain, will be randomized to (1) prasugrel (a 60 mg oral loading and a 10-mg dailiy maintenance dose) or to (2) ticagrelor (a 180 mg loading dose and a 90 mg twice daily maintenance dose). The predefined primary end point is infarct sieze on magnetic resonance imaging at the end of the study (6 months). Magnetic resonance will be performed at day 1, day 7 and moth 6. Platelet reactivity, biomarkers and clinical outcomes will also be assesed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Prasugrel
Drug: Ticagrelor
60 mg oral bolus plus oral 10 mg once daily
180 mg oral bolus plus oral 90 mg every 12 hours daily
Infarct size
Cardiac magnetic resonance imaging-assessed infarct size of left ventricular mass (%)
Time frame: 6 months
Infarct size
Cardiac magnetic resonance imaging-assessed infarct size of left ventricular mass (%)
Time frame: up to two weeks
Myocardial salvage index
Cardiac magnetic resonance imaging-assessed myocardial salvage index
Time frame: up to two weeks
Microvascular obstruction
Cardiac magnetic resonance imaging-assessed microvascular obstruction
Time frame: up to two weeks
MACE
The rate of MACE defined as the composite of death, reinfarction, new-onset heart failure, or rehospitalization
Time frame: 6 months
Ran from Nov 2015 to primary completion in Oct 2018, 35 months.
Of 134 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's 35 months is close to that.
Counting every sponsor, half of 143 studies reached it within 38 months; a quarter within 19 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Prasugrel · Ticagrelor
ST Elevation Myocardial Infarction →
AORTICA Group